• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Aclarion Inc.

    3/6/24 4:09:09 PM ET
    $ACON
    Medical Specialities
    Health Care
    Get the next $ACON alert in real time by email
    SC 13G 1 ea0201200-13gintra_aclarion.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No     . )*

     

    Aclarion, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.00001 par value per share

     

    (Title of Class of Securities)

     

    655187201

    (CUSIP Number)

     

    February 26, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.☐ Rule 13d-1(b)
    b.☒ Rule 13d-1(c)
    c.☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 655187201

     

     

    1. Names of Reporting Persons.
       
      Mitchell P. Kopin
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
       
    4. Citizenship or Place of Organization          United States of America
       

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
    5. Sole Voting Power 0
     
    6. Shared Voting Power 375,554
     
    7. Sole Dispositive Power 0
     
    8. Shared Dispositive Power 375,554
     

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person     375,554 (see Item 4)
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)   ☐
       
    11. Percent of Class Represented by Amount in Row (9)      4.99% (see Item 4)
       
    12. Type of Reporting Person (See Instructions)
       
      IN; HC

     

    Page 2 of 7

     

     

    CUSIP No. 655187201

     

     

    1. Names of Reporting Persons.
       
      Daniel B. Asher
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
       
    4. Citizenship or Place of Organization          United States of America
       

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
    5. Sole Voting Power 0
     
    6. Shared Voting Power 375,554
     
    7. Sole Dispositive Power 0
     
    8. Shared Dispositive Power 375,554
     

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person     375,554 (see Item 4)
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ☐
       
    11. Percent of Class Represented by Amount in Row (9)      4.99% (see Item 4)
       
    12. Type of Reporting Person (See Instructions)
       
      IN; HC

     

    Page 3 of 7

     

     

    CUSIP No. 655187201

     

     

    1. Names of Reporting Persons.
       
      Intracoastal Capital LLC
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
       
    4. Citizenship or Place of Organization          Delaware
       

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With:
    5. Sole Voting Power 0
     
    6. Shared Voting Power 375,554
     
    7. Sole Dispositive Power 0
     
    8. Shared Dispositive Power 375,554
     

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person     375,554 (see Item 4)
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ☐
       
    11. Percent of Class Represented by Amount in Row (9)     4.99% (see Item 4)
       
    12. Type of Reporting Person (See Instructions)
       
      OO

     

    Page 4 of 7

     

     

    Item 1.

     

    (a)Name of Issuer

     

    Aclarion, Inc. (the “Issuer”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    8181 Arista Place, Suite 100

    Broomfield, Colorado 80021

     

    Item 2.

     

    (a)Name of Person Filing

     

    (b)Address of Principal Business Office or, if none, Residence

     

    (c)Citizenship

     

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the “Reporting Persons”).

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

     

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

     

    The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

     

    (d)

    Title of Class of Securities

     

    Common Stock, $0.00001 par value per share, of the Issuer (the “Common Stock”).

      

    (e)CUSIP Number

     

    655187201

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4.Ownership.

     

    (a)and (b):

     

    (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on February 26, 2024 (the “SPA”) (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on February 27, 2024), each of the Reporting Persons may have been deemed to have beneficial ownership of 217,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA, and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 9.9% of the Common Stock, based on (1) 1,975,585 shares of Common Stock outstanding as of February 26, 2024, as reported by the Issuer, plus (2) 217,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA. The foregoing excludes (I) 434,000 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (“Intracoastal Warrant 1”) because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock and (II) 7,188 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 2”) because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 658,188 shares of Common Stock.

     

    Page 5 of 7

     

     

    (ii) As of the close of business on March 6, 2024, each of the Reporting Persons may have been deemed to have beneficial ownership of 375,554 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1, and all such shares of Common Stock represented beneficial ownership of approximately 4.99% of the Common Stock, based on (1) 1,975,585 shares of Common Stock outstanding as of February 26, 2024, as reported by the Issuer, plus (2) 5,175,000 shares of Common Stock in the aggregate issued at the closing of the transaction contemplated by the SPA and the public offering disclosed by the Issuer and (3) 375,554 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 58,446 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock and (II) 7,188 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 441,188 shares of Common Stock.

     

    (c)Number of shares as to which each Reporting Person has:

     

    (i) Sole power to vote or to direct the vote: 0.

     

    (ii) Shared power to vote or to direct the vote: 375,554.

     

    (iii) Sole power to dispose or to direct the disposition of 0.

     

    (iv) Shared power to dispose or to direct the disposition of 375,554.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 6 of 7

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date:  March 6, 2024  
       
      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher
       
      Intracoastal Capital LLC
       
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

     

     

    Page 7 of 7

     

    Get the next $ACON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACON

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ACON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aclarion Inc.

      SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

      11/13/24 3:06:29 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Aclarion Inc.

      SC 13G - Aclarion, Inc. (0001635077) (Subject)

      9/5/24 4:19:39 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Aclarion Inc. (Amendment)

      SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

      3/29/24 5:00:57 PM ET
      $ACON
      Medical Specialities
      Health Care

    $ACON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

      USC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologiesCLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 20, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location

      5/20/25 6:00:00 AM ET
      $ACON
      Medical Specialities
      Health Care
    • Aclarion Announces Texas Back Institute as New CLARITY Trial Site

      Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient careCLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back

      5/12/25 7:34:07 AM ET
      $ACON
      Medical Specialities
      Health Care
    • Aclarion Welcomes Advocate Health as CLARITY Trial Site

      Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the

      5/5/25 6:00:00 AM ET
      $ACON
      Medical Specialities
      Health Care

    $ACON
    SEC Filings

    See more
    • SEC Form 10-Q filed by Aclarion Inc.

      10-Q - Aclarion, Inc. (0001635077) (Filer)

      5/15/25 7:54:10 AM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form DEF 14A filed by Aclarion Inc.

      DEF 14A - Aclarion, Inc. (0001635077) (Filer)

      5/12/25 8:27:41 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form EFFECT filed by Aclarion Inc.

      EFFECT - Aclarion, Inc. (0001635077) (Filer)

      5/6/25 12:15:15 AM ET
      $ACON
      Medical Specialities
      Health Care

    $ACON
    Leadership Updates

    Live Leadership Updates

    See more

    $ACON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

      CLUE is a Multi-center Trial to Identify how Often Nociscan's AI Data Changes the Initial Treatment Plan for Patients With Chronic Low Back Pain Dr. Justin Kubeck Will Initiate CLUE in New Jersey at Ocean Pain and Spine in Toms River BROOMFIELD, CO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the expansion of the multi-center CLUE Trial to New Jersey. Justin Kubeck, MD, orthopedic spine surgeon and founder of Ocean Pain and Spine in Toms

      8/29/24 6:57:00 AM ET
      $ACON
      Medical Specialities
      Health Care
    • Aclarion Appoints Nicholas Theodore, MD as Principal Investigator for CLARITY Post-Market Trial Evaluating Nociscan in the Diagnosis and Treatment of Chronic Low Back Pain

      Nicholas Theodore, MD, FACS, FAANS, is Director of Neurosurgical Spine Center, Johns Hopkins, and Professor of Neurosurgery, Orthopaedics and Biomedical Engineering CLARITY is a Post-market, Multi-site Trial That Will Further Evaluate the Role of Nociscan in the Diagnosis and Surgical Ttreatment of Chronic Low Back Pain. CLARITY is Targeted to Begin in the Second Half of 2023. BROOMFIELD, CO, May 02, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pa

      5/2/23 7:00:00 AM ET
      $ACON
      Medical Specialities
      Health Care
    • Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor

      Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that George Frey MD, Founder of the Colorado Comprehensive Spine Institute, will advise the company as a key opinion leader (KOL). Dr. Frey is a renowned surgeon and inventor with dozens of US and worldwide patents in medical devices, technologies, and methods. Dr. Frey's experiences as a clinician and entrepreneur will provide valuable direction to Aclarion.

      1/17/23 8:29:31 AM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Thramann Jeffrey John

      4 - Aclarion, Inc. (0001635077) (Issuer)

      3/28/23 8:30:04 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form 4: Thramann Jeffrey John bought $1,000 worth of Series A Preferred Stock (1 units at $1,000.00)

      4 - Aclarion, Inc. (0001635077) (Issuer)

      2/21/23 4:02:40 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form 4: Ness Brent bought $9,769 worth of shares (18,500 units at $0.53), increasing direct ownership by 1,850% to 19,500 units

      4 - Aclarion, Inc. (0001635077) (Issuer)

      12/29/22 7:57:11 PM ET
      $ACON
      Medical Specialities
      Health Care